Related references
Note: Only part of the references are listed.Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients EDITORIAL COMMENT
Rishi R. Sekar et al.
UROLOGY (2023)
Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
Victor M. Schuettfort et al.
WORLD JOURNAL OF UROLOGY (2021)
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712A Randomized Phase II Trial
John J. Coen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial
Ethan Basch et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2017)
Incidence and Mortality of Bladder Cancer and their Relationship with Development in Asia
Reza Pakzad et al.
Asian Pacific Journal of Cancer Prevention (2015)
A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)
Giorgio Arcangeli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
Timur Mitin et al.
LANCET ONCOLOGY (2013)
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
Nicholas D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sex and Racial Differences in Bladder Cancer Presentation and Mortality in the US
Emil Scosyrev et al.
CANCER (2009)
COMBINED-MODALITY THERAPY WITH GEMCITABINE AND RADIATION THERAPY AS A BLADDER PRESERVATION STRATEGY: LONG-TERM RESULTS OF A PHASE I TRIAL
Kevin S. Oh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
The present and future burden of urinary bladder cancer in the world
Martine Ploeg et al.
WORLD JOURNAL OF UROLOGY (2009)
Combined systemic therapy and radiotherapy for bladder cancer
Claus Roedel et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2007)
A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer
B Patel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
A randomised trial of accelerated radiotherapy for localised invasive bladder cancer
A Horwich et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial
E Kent et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Combined-modality treatment and selective organ preservation in invasive bladder cancer:: Long-term results
C Rödel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
